Xbiotech Inc.

  • Earnings Score
  • Safety Score
  • Market Cap $194.94M
  • PE -6
  • Debt $10.00M
  • Cash $183.12M
  • EV $21.82M
  • FCF -$29.19M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$32.66M
EBIT-$32.75M
ROE-17%
ROA-16%
FCF-$29.19M
Equity$192.12M
Growth Stability-15%
PE-5.97
PEG-1.72K
PB1.01
P/FCF-6.68
Price/Cash0.94
Debt/Equity0.05
Debt/FCF-0.34
Earnings CAGR0%
Sales CAGR-4%
FCF CAGR-0%
Equity CAGR19%
Earnings Stability0
Earnings Growth YoY-32%
Earnings Growth QoQ-61%
Earnings CAGR 5Y0%
Sales CAGR 5Y-22%
FCF CAGR 5Y-0%
Equity CAGR 5Y-17%
Earnings CAGR 3Y-26%
Sales CAGR 3Y-26%
Equity CAGR 3Y-11%
Market Cap$194.94M
Assets$209.85M
Total Debt$10.00M
Cash$183.12M
Shares Outstanding30.46M
EV21.82M
Earnings Score6%
Safety Score35%
Working Capital169.04M
Current Ratio11.57
Shares Growth 3y0%
Equity Growth QoQ-2%
Equity Growth YoY-14%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.

SEC Filings

Direct access to Xbiotech Inc. (XBIT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Xbiotech Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Xbiotech Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 0%
Stability 0%
loading chart...

Xbiotech Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Xbiotech Inc..

= -$292M
012345678910TV
fcf-$29M-$29M-$29M-$29M-$29M-$29M-$29M-$29M-$29M-$29M-$29M-$292M
DCF-$27M-$24M-$22M-$20M-$18M-$16M-$15M-$14M-$12M-$11M-$112M
Value-$292M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins-------26%-95%-820%--
ROA--34%-79%-53%-47%88%-4%-9%-14%-11%-16%
ROE--36%-86%-55%-51%88%-3%-6%-14%-11%-17%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF----------0-0.34
Debt over Equity---------00.05
Growth Stability-------5%-8%-15%--15%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth--------58%-78%-100%-22%
Earnings YoY growth-73%35%-35%-36%-3K%-102%55%89%-25%0%
Equity YoY growth-75%-43%2%-31%2K%-54%-23%-11%-9%-17%
FCF YoY growth-216%33%-36%-52%11%273%-196%-123%24%-0%